TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Explore this paper's citation graph
Summary
The data suggest that TLR5 decoy receptor–based biologics represent a novel and safe A&bgr;-selective class of biotherapy in AD.
- Type
- article
- Published
- 2018-08-29
- Cited by
- 59
- References
- 69
- Access
- Open access
- OpenAlex
- https://openalex.org/W2888826632
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:52127475
Keywords
Decoy, Disease, Medicine, TLR5, Amyloid (mycology)
References
- NIH Image to ImageJ: 25 years of Image Analysis
- The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
- Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging
- Immune attack: the role of inflammation in Alzheimer disease
- Genetic Studies of Quantitative MCI and AD Phenotypes in ADNI: Progress, Opportunities, and Plans
- Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
- Dual staining assessment of Schwann cell viability within whole peripheral nerves using calcein-AM and ethidium homodimer.
- Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition
- Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain
- Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.
- Alzheimer's disease risk genes and mechanisms of disease pathogenesis
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
- Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice
- Burrowing in rodents: a sensitive method for detecting behavioral dysfunction
- Negative regulation of Toll-like receptor-mediated immune responses
- Optical biosensing: Kinetics of protein A‐IGG binding using biolayer interferometry
- A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
- Assessing Burrowing, Nest Construction, and Hoarding in Mice
- Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
Cited by
- Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
- Toll like receptors as a novel therapeutic target for natural products against chronic diseases.
- Dysregulation of TLR5 and TAM Ligands in the Alzheimer’s Brain as Contributors to Disease Progression
- Toll-like receptors in the pathogenesis of neuroinflammation.
- Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms
- ADSoluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression
- Cell Type Specific Expression of Toll-Like Receptors in Human Brains and Implications in Alzheimer's Disease
- Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression
- Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis
- Receptores neurais e a doença de Alzheimer: uma revisão sistemática da literatura sobre as famílias de receptores mais associadas a doença, suas funções e áreas de expressão
- Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program.
- β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia
- Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis
- An analysis of genetically regulated gene expression across multiple tissues implicates novel gene candidates in Alzheimer’s disease
- Toll-like receptors in Alzheimer's disease.
- Gene therapy for Alzheimer's Disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation.
- Activation of Toll-like receptor 5 in microglia modulates their function and triggers neuronal injury
- Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
- Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses
- Microglia show differential transcriptomic response to Aβ peptide aggregates ex vivo and in vivo
Related papers
- TLR5-derived, TIR-interacting decoy peptides to inhibit TLR signaling
- Pitfalls in the quantitative estimation of β-amyloid immunoreactivity in human brain tissue
- Degradation of Serum Amyloid A in Amyloid‐Susceptible and Amyloid‐Resistant Mouse Strains
- Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease
- Tanshinones inhibit amyloid aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect cultured cells.
- Aromadendrin: a dual amyloid promoter to accelerate fibrillization and reduce cytotoxicity of both amyloid-β and hIAPP
- Insight into amyloid interactions and aggregation processes: Molecular dynamics simulations of amyloid fragments and full-length oligomers
- A fluorescent amyloid sensor for quantitative super-resolution imaging of amyloid fibril assembly.
- Plasma amyloid and in vivo brain amyloid in late middle-aged Hispanics